Device
Melphalan/HDS
Melphalan/HDS is a medical device with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
67%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(1)
Other(1)
Detailed Status
unknown1
Completed1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (66.7%)
Phase 31 (33.3%)
Trials by Status
unknown133%
completed133%
withdrawn133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_3
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
NCT02678572
unknownphase_2
Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
NCT03086993
withdrawnphase_2
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
NCT02406508
Clinical Trials (3)
Showing 3 of 3 trials
NCT02678572Phase 3
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
NCT03086993Phase 2
Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
NCT02406508Phase 2
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
All 3 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 3